Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company pioneering therapies to combat cancer treatment resistance. This news hub provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in precision oncology.
Access consolidated information about ORIC's progress in developing small molecule inhibitors targeting hormone-dependent cancers and resistant tumor mechanisms. The page serves as a historical archive and current awareness tool for tracking milestones in therapeutic innovation.
Key updates include:
Clinical trial advancements for oral therapies addressing treatment-refractory cancers
Research collaborations leveraging AI-driven drug discovery platforms
Regulatory milestones and FDA designations for novel oncology candidates
Bookmark this page for streamlined monitoring of ORIC's progress in overcoming cancer resistance through targeted therapeutic strategies. Check regularly for verified updates directly tied to the company's public disclosures.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced the clearance of its Clinical Trial Application for ORIC-114 in South Korea, focusing on treating cancers with EGFR and HER2 exon 20 insertion mutations. This marks the third regulatory clearance in eight months, highlighting ORIC's commitment to advancing its clinical portfolio. The company is set to initiate a Phase 1 study for ORIC-114, anticipating initial data in the first half of 2023. ORIC has enough cash to support its operations into 2024 and plans five clinical updates across four programs by mid-2023.
ORIC Pharmaceuticals recently announced updates on its clinical programs and upcoming milestones. The company is on track to provide data from its ongoing clinical trials in 2022 and 2023, including ORIC-101, ORIC-533, ORIC-114, and ORIC-944. ORIC holds approximately $280.8 million in cash and investments, projected to fund operations into early 2024. CEO Jacob M. Chacko highlighted the advancements made in 2021, such as IND submissions and strengthening the company’s financial position.
ORIC Pharmaceuticals announced that Dr. Jacob Chacko, CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:00 p.m. ET. The presentation can be accessed via the investor section of their website, with a replay available for 30 days post-event.
ORIC focuses on overcoming therapeutic resistance in cancer with key candidates including ORIC-101, in Phase 1b trials, and other products targeting various cancers. For more information, visit oricpharma.com.
ORIC Pharmaceuticals announced promising preclinical data for ORIC-533, a potent CD73 inhibitor for multiple myeloma, showcasing its potential to overcome immunosuppression. The drug demonstrated significant activity in assays from patients, indicating potential as a single-agent therapy. A Phase 1 trial is set to start in Q4 2021. Additional updates include progress on ORIC-114 and ORIC-944, with trials expected in early 2022. The data highlights the need for effective treatments in patients exhibiting therapeutic resistance.
ORIC Pharmaceuticals, focused on therapies for cancer resistance, is hosting a conference call on December 13, 2021, at 5:30 p.m. ET to discuss their CD73 inhibitor for multiple myeloma. Senior author Dr. Kenneth Anderson will highlight new ex vivo data presented at the ASH Annual Meeting, showcasing how CD73 inhibition combats immune suppression and boosts antitumor activity. The ASH presentation occurs on December 12, 2021. This event aims to provide insights into the clinical potential of ORIC-533, a molecule targeting key resistance pathways in cancer.
ORIC Pharmaceuticals, a clinical stage oncology company, will participate in two upcoming investor conferences. The Jefferies London Health Conference is scheduled for November 18, 2021, at 8:00 a.m. GMT, followed by the Evercore ISI 4th Annual HealthconX Conference on December 2, 2021, at 3:55 p.m. ET. Both events will feature virtual fireside chats available on their website. ORIC is focused on developing cancer treatments targeting therapeutic resistance, with lead candidate ORIC-101 currently in Phase 1b trials.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced the appointment of Dr. Angie You to its board of directors, effective immediately. Dr. You, the current CEO of Amunix Pharmaceuticals, brings extensive experience in venture capital and business development, which ORIC believes will strengthen its leadership as it advances its oncology pipeline. Concurrently, Carl L. Gordon, Ph.D., resigned from the board. ORIC is focused on developing innovative cancer therapies, with lead candidate ORIC-101 currently in Phase 1b trials targeting therapeutic resistance in solid tumors.
ORIC Pharmaceuticals reported financial results for Q3 2021, highlighting a cash position of $296.5 million expected to fund operations into 2024. Initial clinical data from the Phase 1b trial of ORIC-101 in combination with enzalutamide showed a safe profile and preliminary antitumor activity in metastatic prostate cancer. The company also submitted a CTA for ORIC-114 and plans to initiate a Phase 1 trial for ORIC-533 in multiple myeloma. R&D expenses rose to $12.9 million, reflecting increased efforts on product candidates.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced significant advancements regarding ORIC-533, a potent CD73 inhibitor, expected to begin Phase 1 trials in patients with multiple myeloma in 4Q 2021. A preclinical study presented at the ASH Annual Meeting revealed that CD73 inhibition effectively reversed immune suppression and enhanced T-cell activity against tumor cells in relapsed or refractory multiple myeloma patients. The findings highlight the potential of ORIC-533 to improve cancer treatments by overcoming therapeutic resistance.
ORIC Pharmaceuticals has announced initial data from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide for metastatic prostate cancer. The combination was well tolerated, with adverse events aligning with enzalutamide alone. ORIC-101 showed effective GR suppression and maintained target plasma concentrations without drug-drug interaction. Notably, in patients with moderate to high GR expression, there’s evidence of extended treatment duration. ORIC-114 demonstrated compelling preclinical activity in HER2-positive breast cancer.
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
